BLIS Technologies

BLIS Technologies Limited is reporting revenue growth of 23% and ebitda of $0.5m for the first quarter, ending June 30, 2024.

Revenue for 1Q25 was $3.4m, an increase of $0.6m compared with the same period past year. Ebitda was up $0.5m on the breakeven result from 1Q24.

The biotechnology company commenced business in August 2000 when it acquired, from the University of Otago, rights to Salivaricin B, a substance that acts as a natural antibiotic to control streptococcal throat infections. Since then, it has acquired the university's collection of several thousand BLIS (bacteriocin-like-inhibitory substances) producing organisms collected over 25 years by Professor John Tagg, now a consultant to the company.

Chief executive officer Scott Johnson said the outlook for the FY25 year was double-digit revenue growth on FY24 and an ebitda result similar to last year, noting the result will include a material investment in China regulatory access of $0.5m.

Company Details

Registered Office: 399 Moray Place, Dunedin Central Dunedin 9016

Postal Address: 399 Moray Place, Dunedin Central Dunedin 9016

Telephone: +64-347-41338

Facsimile: n/a

Website: http://www.blis.co.nz/

First Listed: 30/07/2001

Balance Date: 31 March

AGM: 21/08/2025

Directors and Executives

Anita Johansen

Director

Scott Johnson

Chief Executive Officer

Aimee McCammon

Independent Director

Geoff Plunket

Chair

Barry Richardson

Independent Director

Dr Alison Stewart

Independent Director

Richard Wingham

Chief Financial Officer

Announcements

Title	Date	Type
Probi agreement enhanced to strengthen alliance	Tue, Oct 28 2025 08:30 am	MKTUPDTE
Two New Patents Strengthen BLIS Global IP Position	Fri, Sep 19 2025 02:01 pm	MKTUPDTE
Retirement of Director	Mon, Sep 15 2025 11:34 am	ADMIN
2025 Annual Shareholder Meeting Results Announcement	Thu, Aug 21 2025 01:44 pm	MEETING
2025 Annual Meeting of Shareholders	Thu, Aug 21 2025 11:00 am	MEETING
Revenue growth with one off cost pressures impacting profit	Mon, Aug 18 2025 08:30 am	MKTUPDTE
Notice of meeting and proxy form	Wed, Jul 23 2025 08:30 am	MEETING
Patent issue settled and new 5 year agreement with BSP	Wed, Jul 02 2025 08:30 am	MKTUPDTE
2025 Annual Shareholder Meeting and Director Nominations	Tue, Jun 24 2025 08:30 am	MEETING
Revenue and earnings growth	Thu, May 22 2025 08:30 am	FLLYR

Major Holdings Announcements

Date	Name	No. Held	%	Current
28/02/23	Roger Norman Macassey and Mark Andr	142,213,158	-	11.16
07/07/21	Probi Aktiebolag	166,148,034	-	13.04
18/05/20	Wen Yi	53,280,077	5.83	4.81
27/03/18	W. Wu	-	6.83	-
06/03/17	Edinburgh Equity Limited	31,157,388	5.59	2.81
08/02/17	Mingchun Qiu	39,000,000	5.50	3.52

Director’s Interests Announcements

Date	Name	No. Held	%	Details	Other
22/03/24	Scott Johnson	5,965,860	-	-	-
25/03/22	Brian David Watson	4,730,431	-	-	-
09/03/20	Anthony Paul Offen	31,157,388	-	-	-
06/03/20	Alison Stewart	350,000	-	-	-
11/04/19	Geoffrey Phil Plunket	800,000	-	-	-
05/04/19	Alison Barrass	200,000	-	-	-
03/08/18	Barry Charles Richardso 17,903,625	-	-		-
01/12/16	Timothy James Mepham	55,977	0.01	-	-

Analysts’ Forecasts

No forecasts available

Disclaimer

Data on this page is from BusinessDesk and NZX Ltd for information purposes only. Details are believed to be accurate but no warranty is given as to accuracy, timeliness, reliability or completeness. No person should rely on the contents of the report and all persons should obtain independent professional advice before acting on any information connected with or contained in this report.

Last Updated: 04/09/2025